Auto-generated challenge from hypothesis h-var-7c976d9fb7 (composite_score=0.812). Target gene: TREM2. Source hypothesis title: TREM2-Mediated Microglial Dysfunction Disrupts Perivascular Tau Clearance. Success criteria: 1. TREM2 agonist (AL002 or equivalent) increases perivascular macrophage tau uptake by >40% ex vivo. 2. Tau burden in perivascular regions decreases by >30% vs. vehicle in PS19 tauopathy mice. 3. cerebral spinal fluid (CSF) tau levels decline by >20% after 8 weeks. 4. No increase in inflammatory cytokine release (IL-6, TNF-alpha) vs. baseline.